Correct administration for optimum efficacy

The correct administration of Dymista® will lead to optimum efficacy, thereby increasing patient compliance

The correct use of Dymista® is imperative for optimum efficacy and to minimise side effects. Patients should be shown how to use Dymista® following the simple step by step instructions or watching the how to use video


Dymista® Administration

Click to watch video

A common side effect of Dymista® is dysgeusial1, which can often be alleviated by correct inhalation technique and not sniffing the medication to the back of the throat immediately after spraying.

Correct administration technique

  • Shake the bottle gently for 5 seconds by tilting it upwards and downwards and then remove the protective cap.

The first time the nasal spray is used, you must prime the pump

  • Put one linger either side of the spray pump and place your thumb cm the bottom of the bottle
  • Press dawn and release the pump 6 times until a fine mist appears.
  • Now your pump is primed and ready to use.
  • If the nasal spray has not been used for more than 7 days, you will need to re-prime the pump once by pressing down and releasing the pump.

Using the spray

  • After blowing your nose, spray once into each nostril keeping the head fitted downward.
  • The spray tip should be directed to the outside wall of the nose, using the right hand for the left nostril and the left hand for the right nostril
  • Do not sniff, breathe in gently.
  • After use, wipe the spray lip and replace the protective cap.

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
  • Impact
  • Guidelines
  • Clinical Papers
    Clinical Papers


  1. Price D Bousquet J. Bachert C el al. MP29.o2 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month trial. Presented at EEAACI Geneva 16-21 June 2013. Patients were chronic AR patients treated over 12 months at the recommended dosages. Dymista® (n=404). FP (n=207)

Want to expand your knowledge…

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Viatris Connect

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.